Year-end Sale % OFF 
Abstract
Acute myeloid leukemia (AML) is the most common subtype of acute leukemia in adult. Combined chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the major treatment of AML. In recent years, as a newly developed immunotherapy, chimeric antigen receptor T cell (CAR-T) immunotherapy has achieved remarkable effect in the treatment of B cells malignant tumor. In the treatment of AML, CAR-T immunotherapy has also made new progresses, and the current research foci are mainly on the selection of treatment targets and the improvement of CAR-T preparation technology. This article presents an overview of the current status of pre-clinical and clinical trials, and the limitations of CAR-T immunotherapy in treatment of AML. Key words: Leukemia, myeloid, acute; Immunotherapy, adoptive; Hematopoietic stem cell transplantation; Clinical protocols; Molecular targeted therapy; Chimeric antigen receptor T cell immunotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
